CPRX
Catalyst Pharmaceuticals Inc.
$19.78
-$0.62(-3.04%)
55
Overall
80
Value
18
Tech
68
Quality
Market Cap
$2.42B
Volume
3.56M
52W Range
$19.15 - $26.58
Target Price
$34.00
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | -- | -- | -- | $500.0K | $102.3M | $119.1M | $140.8M | $214.2M | $398.2M | $491.7M | ||
| Total Revenue | -- | -- | -- | $500.0K | $102.3M | $119.1M | $140.8M | $214.2M | $398.2M | $491.7M | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | -- | -- | -- | -- | $14.8M | $17.0M | $21.9M | $34.4M | $52.0M | $68.8M | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | -- | -- | -- | $500.0K | $87.5M | $102.0M | $118.9M | $179.8M | $346.2M | $422.9M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $-20.4M | $-19.3M | $-18.7M | $35.8M | $55.7M | $60.7M | $66.6M | $78.0M | $226.9M | $190.4M | ||
| Research & Development | $11.8M | $11.4M | $11.4M | $19.9M | $18.8M | $16.5M | $16.9M | $19.8M | $93.2M | $12.6M | ||
| Research Expense | $11.8M | $11.4M | $11.4M | $19.9M | $18.8M | $16.5M | $16.9M | $19.8M | $93.2M | $12.6M | ||
| Selling, General & Administrative | $8.6M | $7.9M | $7.3M | $15.9M | $36.9M | $44.2M | $49.6M | $57.1M | $133.7M | $177.7M | ||
| Selling & Marketing Expenses | -- | -- | -- | $15.9M | -- | -- | -- | -- | $91.5M | $118.7M | ||
| General & Administrative Expenses | $8.6M | $7.9M | $7.3M | $-242.2K | $36.9M | $44.2M | $49.6M | $57.1M | $133.7M | $177.7M | ||
| Salaries & Wages | $-1.6M | $-1.8M | $-2.4M | $-3.6M | $3.8M | $6.3M | $6.1M | $7.9M | $14.3M | $22.3M | ||
| Depreciation & Amortization | $-34.5K | $-43.4K | $-45.7K | $-38.0K | -- | -- | -- | -- | -- | -- | ||
| Depreciation & Amortization | $-34.5K | $-43.4K | $-45.7K | $-38.0K | -- | -- | -- | -- | -- | -- | ||
| Amortization | -- | -- | -- | -- | -- | -- | -- | $1.1M | $32.6M | $37.4M | ||
| Other Operating Expenses | -- | $-10.0K | $-10.0K | -- | $296.3K | $300.0K | $400.0K | $431.0K | $226.9M | $190.4M | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-20.4M | $-19.3M | $-18.7M | $-35.3M | $31.8M | $41.3M | $52.4M | $101.8M | $86.8M | $195.1M | ||
| EBITDA | $-20.2M | $-18.0M | $-18.4M | $-34.0M | $33.5M | $41.4M | $52.6M | $106.0M | $127.4M | $254.0M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Gain on Sale of Securities | -- | -- | -- | $20.2K | $80.0K | -- | -- | -- | $3.0M | $5.1M | ||
| Other Income/Expense | $-165.4K | $-1.2M | $-267.3K | $-1.3M | $-1.6M | $-587.0K | $-282.0K | $2.9M | $-7.7M | $-21.1M | ||
| Other Special Charges | $165.4K | $1.2M | $267.3K | $1.3M | $1.6M | $587.0K | $282.0K | $2.9M | $7.7M | $21.1M | ||
| SPECIAL ITEMS | ||||||||||||
| Special Income Charges | $-3.5M | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-20.2M | $-18.1M | $-18.4M | $-34.0M | $33.4M | $41.3M | $52.4M | $104.7M | $94.5M | $216.3M | ||
| Pre-Tax Income | $-20.2M | $-18.1M | $-18.4M | $-34.0M | $33.4M | $41.9M | $52.7M | $104.7M | $94.5M | $216.3M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | -- | -- | -- | -- | $1.5M | $-33.1M | $13.2M | $21.6M | $23.1M | $52.4M | ||
| NET INCOME | ||||||||||||
| Net Income | $-20.2M | $-18.1M | $-18.4M | $-34.0M | $31.9M | $75.0M | $39.5M | $83.1M | $71.4M | $163.9M | ||
| Net Income (Continuing Operations) | $-20.2M | $-18.1M | $-18.4M | $-34.0M | $31.9M | $75.0M | $39.5M | $83.1M | $71.4M | $163.9M | ||
| Net Income (Discontinued Operations) | $-20.2M | $-18.1M | $-18.4M | $-34.0M | $31.9M | $75.0M | $39.5M | $83.1M | $71.4M | $163.9M | ||
| Net Income (Common Stockholders) | $-20.2M | $-18.1M | $-18.4M | $-34.0M | $31.9M | $75.0M | $39.5M | $83.1M | $71.4M | $163.9M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $214.1M | ||
| TOTALS | ||||||||||||
| Total Expenses | $-20.4M | $-19.3M | $-18.7M | $35.8M | $70.5M | $77.8M | $88.4M | $112.4M | $278.8M | $259.2M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $80.9M | $82.9M | $85.8M | $102.6M | $102.9M | $103.5M | $103.4M | $103.4M | $106.3M | $118.5M | ||
| Average Shares Outstanding (Diluted) | $80.9M | $82.1M | $87.7M | $102.6M | $106.0M | $106.2M | $107.8M | $111.4M | $113.8M | $124.9M | ||
| Shares Outstanding | $82.9M | $83.0M | $102.6M | $102.7M | $103.4M | $103.8M | $102.7M | $105.7M | $117.9M | $121.4M | ||
| Basic EPS | -- | -- | -- | $-0.33 | $0.31 | $0.72 | $0.38 | $0.80 | $0.67 | $1.38 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | $0.31 | $0.72 | $0.38 | $0.80 | $0.67 | $1.38 | ||
| Diluted EPS | $-0.25 | $-0.22 | $-0.21 | $-0.33 | $0.30 | $0.71 | $0.37 | $0.75 | $0.63 | $1.31 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | $0.30 | $0.71 | $0.37 | $0.75 | $0.63 | $1.31 | ||
| OTHER METRICS | ||||||||||||
| Non Recurring Operation Expense | $3.5M | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Other Gand A | $8.6M | $7.9M | $7.3M | $-242.2K | $36.9M | $44.2M | $49.6M | $57.1M | $133.7M | $177.7M | ||
| Rent And Landing Fees | $8.6M | $7.9M | $7.3M | $-242.2K | $318.3K | $278.8K | -- | -- | -- | -- | ||
| Selling Expense | -- | -- | -- | $15.9M | -- | -- | -- | -- | $91.5M | $118.7M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CPRX | $19.78 | -3.0% | 3.56M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Catalyst Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW